Genentech's broad metastatic breast cancer claim for Avastin (bevacizumab) appears to be destined for withdrawal, but the company may have the potential to test its effectiveness in specific subpopulations. Two new clinical trials clearly did not provide enough data for FDA's Oncology Drugs Advisory Committee to support moving the drug to full approval for use with paclitaxel in first-line treatment of metastatic breast cancer, voting 13-0 against it July 20.Committee members also soundly rejected...